fbpx
Pure Medical unquoted UK equities
Days
Hours
Minutes
Seconds
Raised | £375,140
Target | £2,500,000
Share price | £25.15
We’re Pure Medical, an early-stage health and wellness company that is seeking equity investment funding of £2.5m. We provide services that help patients stay healthy and out of the hospital. Our mission is to make high-quality innovative healthcare accessible and affordable to everyone.
PURE RESTORE HEALTH

companies-house

  • The Health & Wellness market was valued at £23bn in the UK in 2020
  • 2022E and 2023E Projected Revenue Based on Achievable and Visible Contract Pipeline of ~£120M

Unquoted UK equities

Access Pure Medical’s unquoted – unlisted – equities, and healthcare shares of a UK private limited company that are not traded on a recognised stock exchange, such as the London Stock Exchange.
Pure Medical has EIS and SEIS advance assurance from HMRC.

THE OPPORTUNITY

Pain and Ageing are universal problems. Pure Medical utilizes the latest in healthcare technologies and proactive wellness services to help people feel their best.

Pure Restore Health

THE PROBLEM & THE SOLUTION
Over 15 million people in England have long-term conditions or chronic diseases for which there is no cure using conventional medicine and are currently managed by drugs and so are dependent on long-term medications.

 

The UK Health & Wellness market is estimated at £23bn with 8% CAGR. With our scalable B2B & B2C wellness solution we are aiming to take advantage of that growth, with packages for innovative treatment and therapies, to deliver on our mission to make healthcare accessible to everyone.

 

We are relentless in our search for healthcare innovation and alternatives that facilitate patient wellbeing without negatively affecting our planet and with the certainty that we are generating a positive economic, social and environmental impact. We are taking actionable steps to deliver next-generation patient experiences and outcomes, venturing outside of the conventional healthcare industry and utilising the latest technology to gain valuable insights and ideas to improve our patient’s journey.

 

We are raising to scale up sales and marketing, further develop our technology and to take on key hires.
Treatments provided at Pure Medical

Equity for health - Unquoted UK Equities

Invest in stem cells

the building blocks
of the body

Producing the next generation of IPSCs
Induced pluripotent stem cells therapies

Pure Medical’s Offering

We offer a broad spectrum of innovative health services

Digital Health Service

Talk to a doctor

Digital triage

Monitor

Symptom Checker

You can consult with a
clinician whenever you like

We handpick Pure Medical’s expert doctors, physiotherapists, nurses, and pharmacists, who follow the strictest clinical guidelines.

Digital Health Service

Take control of your health and wellness

Access innovative treatments when you need them.

A better way to track wellness

Pure Medical Monitor allows you to see how your habits affect your health. Pure medical monitor allows you to connect your health data from your phone, wearables, and apps into one convenient location.

Fundraise Highlights

£2.5M

Offer for subscription to raise £2.5 million to fund Equity for Health (subject to increase at the discretion of the Directors to no more than £50 million).

£23 Billion

The Health & Wellness market was valued at £23bn in the UK in 2020¹ | CAGR: 8.8% | Pure Medical is well-positioned in that it has the competitive advantage of being first to market in the UK.

Pure Medical Group - Hyper Baric Oxygen Therapy - HBOT

~£120M Contract Pipeline

Path to 2022E and 2023E Projected Revenue Based on Achievable and Visible Contract Pipeline of ~£120M¹ with Upside Potential

UK £25.15

New Shares will be issued at a price of £25.15 per share with a minimum subscription of two shares in Equity for Health, the opportunity to purchase unlisted shares in the fastest growing technical healthcare provider.

Class B Shares pre-emption right

For every share purchased in this round, investors also receive a pre-emption right to (at their option) purchase an additional share of common stock at £25.15 per share in the company’s next fundraising round.

More Info on the Class B PRE-EMPTION RIGHTS

One notable component of our £25.15 price is that each share issued in this round is paired with a pre-emption right to purchase an additional share of common stock for £25.15 in Pure Medical’s next funding round offering. We believe this will be compelling especially among investors that want to participate in future raises, given the forecast change in share price between now and then.

Partners & Customers Including:

NHS

Circle

BMI

Queens Square PH

Who We Are

Executive Management and Board

Gary McCauley
Gary McCauley
CEO, Founder
Gary McCauley
CEO, Founder

“With all the advancements in science, medicine, and technology, we, as humans, are capable of so much more, living better lives with increased levels of vitality, above and beyond what we have ever experienced. Our goal is to bring these advancements to as many people as possible.”

​As an entrepreneur with an extensive operations background and a proven track record in successfully scaling healthcare brands, Gary is on a mission to make Pure Medical a UK household brand, leading the way in longevity and health optimisation.

Gary brings over 25 years of executive board experience running high growth companies experiencing significant scale. Gary is a founding member of Pure Medical. Most recently, he served as Managing Director at HTTC Healthcare – Poseidonia where he spent 2 years. Gary continues to serve on the Executive Board of a global biopharmaceutical group. In his role at HTTC Healthcare, Gary was responsible for strategic and financial planning, financial accounting, and global team leadership.

Pure Medical - Chief Medical Officer - Dr John Howe
Dr John Howe
Chief Medical Officer
Dr John Howe
Chief Medical Officer, Director

Dr John Howe MBBS BSc MRCGP graduated from Imperial College London, obtaining dual degrees in both Medicine and Healthcare Management. Dr Howe completed post-graduate training in the United Kingdom and Australia, specializing in General Practice. After a three-year period serving as a cruise ship physician, Dr Howe successfully ran his own clinic in Kazakhstan.

Most recently Dr Howe served as Chief Medical Officer to an Estonian telemedicine platform as the company prepared to launch its platform to six million patients in India. There, he led doctor recruitment and set the standards in clinical quality assurance.

Dr Anna Davidsson
Dr Anna Davidsson
Director
Dr Anna Davidsson
Director

Dr Anna Davidsson is a highly qualified physician with more than ten years of expertise. She has worked as a doctor in both the United Kingdom and Iceland. She is well-positioned to support Pure Medical’s expansion objectives, as she has substantial managerial expertise.

Pure Medical Group - Director - Dr David Yakobi
Dr David Yakobi
Director, Cardiac Surgeon
Dr David Yakobi
Director, Cardiac Surgeon

Dr David Yakobi is a Board-Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr Yakobi has vast experience in Coronary Artery Disease, Valvular disease, and Paediatric congenital heart disease.

Dale Steele
Dale Steele
Co-founder, Director
Dale Steele
Co-Founder, COO

Dale brings with him over 20 years of experience running operational teams at high growth companies experiencing significant scale. Dale co-founded Pure Medical previously holding positions at HTTC Medical – Poseidonia Healthcare, where he spent 2 years and served on the UK Board of Directors. Dale continues to serve on the executive board of the global biopharmaceutical company.

Contact Pure Medical

UNQUOTED UK EQUITIES

Days
Hours
Minutes
Seconds
15%
0%
Raised
£375,140
Target
£2,500,000
Share price
£25.15
We’re Pure Medical, an early-stage health and wellness company that is seeking equity investment funding of £2.5m. We provide services that help patients stay healthy and out of the hospital. Our mission is to make high-quality innovative healthcare accessible and affordable to everyone.

companies-house

  • The Health & Wellness market was valued at £23bn in the UK in 2020
  • 2022E and 2023E Projected Revenue Based on Achievable and Visible Contract Pipeline of ~£120M

Unquoted UK equities

Access Pure Medical’s unquoted – unlisted – equities, and healthcare shares of a UK private limited company that are not traded on a recognised stock exchange, such as the London Stock Exchange.
Pure Medical has EIS and SEIS advance assurance from HMRC.

THE OPPORTUNITY

Pain and Ageing are universal problems. Pure Medical utilizes the latest in healthcare technologies and proactive wellness services to help people feel their best.

Pure Restore Health

THE PROBLEM & THE SOLUTION
Over 15 million people in England have long-term conditions or chronic diseases for which there is no cure using conventional medicine and are currently managed by drugs and so are dependent on long-term medications.

 

The UK Health & Wellness market is estimated at £23bn with 8% CAGR. With our scalable B2B & B2C wellness solution we are aiming to take advantage of that growth, with packages for innovative treatment and therapies, to deliver on our mission to make healthcare accessible to everyone.

 

We are relentless in our search for healthcare innovation and alternatives that facilitate patient wellbeing without negatively affecting our planet and with the certainty that we are generating a positive economic, social and environmental impact. We are taking actionable steps to deliver next-generation patient experiences and outcomes, venturing outside of the conventional healthcare industry and utilising the latest technology to gain valuable insights and ideas to improve our patient’s journey.

 

We are raising to scale up sales and marketing, further develop our technology and to take on key hires.
Treatments provided at Pure Medical

Equity for health - Unquoted UK Equities

Invest in stem cells

the building blocks
of the body

Producing the next generation of IPSCs
Induced pluripotent stem cells therapies

Pure Medical’s Offering

We offer a broad spectrum of innovative health services

Digital Health Service - Unquoted UK Equities

Talk to a doctor

Digital triage

Monitor

Symptom Checker

Take control of your health and wellness

Access innovative treatments when you need them.

Digital Health Service

You can consult with a
clinician whenever you like

We handpick Pure Medical’s expert doctors, physiotherapists, nurses, and pharmacists, who follow the strictest clinical guidelines.

A better way to track wellness

Pure Medical Monitor allows you to see how your habits affect your health. Pure medical monitor allows you to connect your health data from your phone, wearables, and apps into one convenient location.
Fundraise Highlights

£2.5M

Offer for subscription to raise £2.5 million to fund Equity for Health (subject to increase at the discretion of the Directors to no more than £50 million).

£23 Billion

The Health & Wellness market was valued at £23bn in the UK in 2020¹ | CAGR: 8.8% | Pure Medical is well-positioned in that it has the competitive advantage of being first to market in the UK.

~£120M Contract Pipeline

Path to 2022E and 2023E Projected Revenue Based on Achievable and Visible Contract Pipeline of ~£120M¹ with Upside Potential

UK £25.15

New Shares will be issued at a price of £25.15 per share with a minimum subscription of two shares in Equity for Health, the opportunity to purchase unlisted shares in the fastest growing technical healthcare provider.

Class B Shares PRE-EMPTION RIGHTS

For every share purchased in this round, investors also receive a pre-emption right to (at their option) purchase an additional share of common stock at £25.15 per share in the company’s next fundraising round.

More Info on the Class B PRE-EMPTION RIGHTS

One notable component of our £25.15 price is that each share issued in this round is paired with a pre-emption right to purchase an additional share of common stock for £25.15 in Pure Medical’s next funding round offering. We believe this will be compelling especially among investors that want to participate in future raises, given the forecast change in share price between now and then.

Partners & Customers Including:

NHS

Circle

BMI

Queens Square PH

Who We Are

Executive Management and Board

Gary McCauley
Gary McCauley
CEO, Founder
Gary McCauley
CEO, Founder

“With all the advancements in science, medicine, and technology, we, as humans, are capable of so much more, living better lives with increased levels of vitality, above and beyond what we have ever experienced. Our goal is to bring these advancements to as many people as possible.”

​As an entrepreneur with an extensive operations background and a proven track record in successfully scaling healthcare brands, Gary is on a mission to make Pure Medical a UK household brand, leading the way in longevity and health optimisation.

Gary brings over 25 years of executive board experience running high growth companies experiencing significant scale. Gary is a founding member of Pure Medical. Most recently, he served as Managing Director at HTTC Healthcare – Poseidonia where he spent 2 years. Gary continues to serve on the Executive Board for a global biopharmaceutical group. In his role at HTTC Healthcare, Gary was responsible for strategic and financial planning, financial accounting, and global team leadership.

Pure Medical - Chief Medical Officer - Dr John Howe
Dr John Howe
Chief Medical Officer
Dr John Howe
Chief Medical Officer, Director

Dr John Howe MBBS BSc MRCGP graduated from Imperial College London, obtaining dual degrees in both Medicine and Healthcare Management. Dr Howe completed post-graduate training in the United Kingdom and Australia, specializing in General Practice. After a three-year period serving as a cruise ship physician, Dr Howe successfully ran his own clinic in Kazakhstan.

Most recently Dr Howe served as Chief Medical Officer to an Estonian telemedicine platform as the company prepared to launch its platform to six million patients in India. There, he led doctor recruitment and set the standards in clinical quality assurance.

Dr Anna Davidsson
Dr Anna Davidsson
Director
Dr Anna Davidsson
Director

Dr Anna Davidsson is a highly qualified physician with more than ten years of expertise. She has worked as a doctor in both the United Kingdom and Iceland. She is well-positioned to support Pure Medical’s expansion objectives, as she has substantial managerial expertise.

Pure Medical Group - Director - Dr David Yakobi
Dr David Yakobi
Director, Cardiac Surgeon
Dr David Yakobi
Director, Cardiac Surgeon

Dr David Yakobi is a Board-Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr Yakobi has vast experience in Coronary Artery Disease, Valvular disease, and Paediatric congenital heart disease.

Dale Steele
Dale Steele
Co-founder, Director
Dale Steele
Co-Founder, COO

Dale brings with him over 20 years of experience running operational teams at high growth companies experiencing significant scale. Dale co-founded Pure Medical previously holding positions at HTTC Medical – Poseidonia Healthcare, where he spent 2 years and served on the UK Board of Directors. Dale continues to serve on the executive board of a global biopharmaceutical company.

Equity For Health

Pure Restore Health